CN111630046A - 喹唑啉衍生物及其应用 - Google Patents

喹唑啉衍生物及其应用 Download PDF

Info

Publication number
CN111630046A
CN111630046A CN201880081130.9A CN201880081130A CN111630046A CN 111630046 A CN111630046 A CN 111630046A CN 201880081130 A CN201880081130 A CN 201880081130A CN 111630046 A CN111630046 A CN 111630046A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880081130.9A
Other languages
English (en)
Other versions
CN111630046B (zh
Inventor
陈新海
魏霞蔚
张丽
于衍新
周凯
胡伯羽
陈兆国
章晖宇
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU JINRUI JIYE BIO-TECHNOLOGY CO LTD
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN111630046A publication Critical patent/CN111630046A/zh
Application granted granted Critical
Publication of CN111630046B publication Critical patent/CN111630046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及一系列喹唑啉类化合物，尤其是式(I)所示化合物、其异构体或其药学上可接受的盐，其药物组合物以及它们作为Pan‑HER酪氨酸激酶抑制剂的应用。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880081130.9A 2017-12-19 2018-12-19 喹唑啉衍生物及其应用 Active CN111630046B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017113767570 2017-12-19
CN201711376757 2017-12-19
CN201810225742 2018-03-19
CN2018102257422 2018-03-19
CN201810576529 2018-06-05
CN2018105765296 2018-06-05
PCT/CN2018/122016 WO2019120213A1 (zh) 2017-12-19 2018-12-19 喹唑啉衍生物及其应用

Publications (2)

Publication Number Publication Date
CN111630046A true CN111630046A (zh) 2020-09-04
CN111630046B CN111630046B (zh) 2023-01-10

Family

ID=66993104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880081130.9A Active CN111630046B (zh) 2017-12-19 2018-12-19 喹唑啉衍生物及其应用

Country Status (5)

Country Link
US (1) US20210078958A1 (zh)
EP (1) EP3733663B1 (zh)
JP (1) JP7296641B2 (zh)
CN (1) CN111630046B (zh)
WO (1) WO2019120213A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364225A (zh) * 2022-09-23 2022-11-22 成都金瑞基业生物科技有限公司 Pan-HER抑制剂在制备抗卵巢癌药物中的用途
CN116803393A (zh) * 2023-08-24 2023-09-26 成都金瑞基业生物科技有限公司 一种pan-HER抑制剂的药物组合物及其制备方法
CN117567466A (zh) * 2024-01-16 2024-02-20 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971927T3 (es) * 2018-09-18 2024-06-10 Hoffmann La Roche Derivados de quinazolina como agentes antitumorales
WO2020147774A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 喹唑啉衍生物在制备治疗鼻咽癌药物中的应用
WO2020253836A1 (zh) * 2019-06-19 2020-12-24 南京明德新药研发有限公司 喹唑啉类化合物的晶型、盐型及其制备方法
CN114845723B (zh) * 2019-11-01 2024-09-13 正大天晴药业集团股份有限公司 包含喹唑啉衍生物或其盐的药物组合物
CN113278012B (zh) * 2020-02-19 2022-07-12 郑州同源康医药有限公司 用作激酶抑制剂的化合物及其应用
CN111763215B (zh) * 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN112125890B (zh) * 2020-09-25 2022-12-06 华东理工大学 一种含异吲哚酮基喹唑啉基羧酸酯类衍生物及其应用
WO2022266425A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 3-cyano-quinoline derivatives and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN106279128A (zh) * 2015-05-19 2017-01-04 四川海思科制药有限公司 环氧乙烷衍生物及其制备方法和在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
US10633364B2 (en) * 2015-12-25 2020-04-28 Xuanzhu Pharma Co., Ltd. Crystals of quinazoline derivative and preparation method therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN106279128A (zh) * 2015-05-19 2017-01-04 四川海思科制药有限公司 环氧乙烷衍生物及其制备方法和在医药上的应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364225A (zh) * 2022-09-23 2022-11-22 成都金瑞基业生物科技有限公司 Pan-HER抑制剂在制备抗卵巢癌药物中的用途
CN115364225B (zh) * 2022-09-23 2024-06-11 成都金瑞基业生物科技有限公司 Pan-HER抑制剂在制备抗卵巢癌药物中的用途
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法
CN116803393A (zh) * 2023-08-24 2023-09-26 成都金瑞基业生物科技有限公司 一种pan-HER抑制剂的药物组合物及其制备方法
CN116803393B (zh) * 2023-08-24 2023-11-21 成都金瑞基业生物科技有限公司 一种pan-HER抑制剂的药物组合物及其制备方法
CN117567466A (zh) * 2024-01-16 2024-02-20 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法
CN117567466B (zh) * 2024-01-16 2024-04-16 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法

Also Published As

Publication number Publication date
US20210078958A1 (en) 2021-03-18
CN111630046B (zh) 2023-01-10
WO2019120213A1 (zh) 2019-06-27
EP3733663B1 (en) 2023-05-17
EP3733663A1 (en) 2020-11-04
JP7296641B2 (ja) 2023-06-23
JP2021506919A (ja) 2021-02-22
EP3733663A4 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CN111630046B (zh) 喹唑啉衍生物及其应用
ES2938899T3 (es) Compuesto de aril-fósforo-oxígeno como inhibidor de la quinasa del EGFR
CN108659005B (zh) 作为egfr抑制剂的喹唑啉衍生物
WO2023020523A1 (en) Bicyclic derivatives and use thereof
RU2747311C2 (ru) Ингибитор CDK4/6
CN117177744A (zh) Cdk2抑制剂及其使用方法
CN111372937B (zh) 噻吩并二氮杂卓衍生物及其应用
RU2672722C2 (ru) Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
EP4269402A1 (en) Aromatic heterocyclic compound, pharmaceutical composition and use thereof
CN114786778A (zh) 治疗性化合物
TW202231633A (zh) Cdk抑制劑
WO2023215906A1 (en) Kras g12d proteolysis targeting chimeras
WO2023081637A1 (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
CN116438183A (zh) 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
WO2024120424A1 (zh) 一种靶向泛kras蛋白降解剂的化合物及其应用
WO2024044713A1 (en) Naphthyridine compounds for inhibition of raf kinases
TW202430181A (zh) 一種靶向泛kras蛋白降解劑的化合物及其應用
TW202340197A (zh) 一種ｃｃｒ４小分子拮抗劑及其用途
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases
WO2024059558A1 (en) Polycyclic quinazolines for inhibition of erbb2
TW202225163A (zh) 芳香雜環類化合物、藥物組合物及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211029

Address after: 518118 innovation Plaza a2402, No. 2007, Pingshan Avenue, Liulian community, Pingshan street, Pingshan District, Shenzhen, Guangdong

Applicant after: Shenzhen jinruijiye Biotechnology Co.,Ltd.

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221208

Address after: No. 2004, 20th Floor, Building 1, No. 333, North Yizhou Avenue, Chengdu Hi tech Zone, China (Sichuan) Pilot Free Trade Zone, 610000, Sichuan

Applicant after: Chengdu Jinrui Jiye Bio-Technology Co.,Ltd.

Address before: 518118 innovation Plaza a2402, No. 2007, Pingshan Avenue, Liulian community, Pingshan street, Pingshan District, Shenzhen, Guangdong

Applicant before: Shenzhen jinruijiye Biotechnology Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant